ALCJ — Crossject SA Share News
0.000.00%
Last trade - 00:00Europe Research Roundup: Dong Energy, Flybe Group, Genel Energy
Brief: Crossject new headquarters in technology park in Dijon
Brief: Crossject requests pharmaceutical status to ANSM
Brief: Crossject H1 net loss shrinks to 2.8 mln euros
Brief: Crossject delays filing of marketing authorization for Zénéo Adrenaline
Brief: Crossject FY total operating income at 2.4 mln euros
Brief: Crossject signs industrial partnership with Cenexi
Brief: Crossject starts construction of its future buildings
Brief: Crossject partners with Xi'an Xintong Pharmaceutical Research
Brief: Crossject secures 6.7 million euros in funding for the development of three new drugs
Brief: Crossject H1 net loss widens to 3.6 million euros
Brief: Crossject enters into partnering agreement with Sayre Therapeutics
Brief: Crossject confirms development plan for Zeneo Sumatriptan
Brief: Crossject announces five new patents
Brief: Crossject gives details of new buyback programme
Brief: Crossject FY net loss widens to 4.3 mln euros
Corrected: OFFICIAL-BRIEF-Crossject reports positive results with needle free ZENEO Methotrexate
Brief: Crossject reports positive results with needle free ZENEO Methrotrexate
Brief: Crossject joins Enternext PEA-PME 150 Index